Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 1/2018

Open Access 01-01-2018 | Clinical Guides in Oncology

SEOM clinical guidelines for endometrial cancer (2017)

Authors: A. Santaballa, X. Matías-Guiu, A. Redondo, N. Carballo, M. Gil, C. Gómez, M. Gorostidi, M. Gutierrez, A. Gónzalez-Martín

Published in: Clinical and Translational Oncology | Issue 1/2018

Login to get access

Abstract

Endometrial cancer (EC) is the most common gynecological cancer in developed countries. Most patients are diagnosed at an early stage with a low risk of relapse. However, there is a group of patients with a high risk of relapse and poor prognosis. Despite the recent publication of randomized trials, the adjuvant treatment of high-risk EC is still to be defined and there are many open questions about the best approach and the right timing. Unfortunately, the survival of metastatic or recurrent EC is short, due to the poor results of chemotherapy and the lack of a second line of treatment. Advances in the knowledge of the molecular abnormalities in EC have permitted the development of promising targeted therapies.
Literature
1.
Dowty JG, Win AK, Buchanan DD, Lindor NM, Macrae FA, Clendenning M, et al. Cancer risks for MLH1 and MSH2 mutation carriers. Hum Mutat. 2013;34(3):490–7.CrossRefPubMed
2.
Schmeler KM, Lynch HT, Chen LM, Munsell MF, Soliman PT, Clark MB, et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med. 2006;354:261–9.CrossRefPubMed
3.
Kurman RJ, Carcangiu ML, Herrington CS, Young RH. WHO classification of tumors of the female reproductive organs. WHO classification of tumors. Lyon: IARC press; 2014.
4.
Matias-Guiu X, Prat J. Molecular pathology of endometrial carcinoma. Histopathology. 2013;62:111–23.CrossRefPubMed
5.
Cancer Genome Atlas Research Network, Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497:67–73.CrossRef
6.
7.
Colombo N, Creutzberg C, Amant F, Bosse T, González-Martín A, Ledermann J, et al. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up. Ann Oncol. 2016;27(1):16–41.CrossRefPubMed
8.
Benedetti Panici P, Basile S, Maneschi F, Alberto Lissoni A, Signorelli M, Scambia G, et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst. 2008;100(23):1707–16.CrossRefPubMed
9.
Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet. 2009;373(9658):125–36.CrossRefPubMed
10.
Kong A, Jonhson N, Kitchener HC, Lawrie TA. Adjuvant radiotherapy for stage I endometrial cáncer. Cochrane Database Syst Rev. 2012;3:CD003916.
11.
Sorbe B, Nordström B, MäenpääJ Kuhelj J, Kuhelj D, Okkan S, et al. Intravaginal brachytherapy in FIGO stage I low-risk endometrial cancer: a controlled randomized study. Int J Gynecol Cancer. 2009;19(5):873–8.CrossRefPubMed
12.
Nout RA, Smit VT, Putter H, Jurgenliemk-Schulz IM, Jobsen JJ, Lutgens LC, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet. 2010;375:816–23.CrossRefPubMed
13.
Sorbe B, Horvath G, Andersson H, Boman K, Lundgren C, Pettersson B. External pelvic and vaginal irradiation versus vaginal irradiation alone as postoperative therapy in medium-risk endometrial carcinoma—a prospective randomized study. Int J Radiat Oncol Biol Phys. 2012;82:1249–55.CrossRefPubMed
14.
Hogberg T, Signorelli M, de Oliveira CF, Fossati R, Lissoni AA, Sorbe B, et al. Sequential adjuvant chemotherapy and radio-therapy in endometrial cancer: results from two randomised studies. Eur J Cancer. 2010;46:2422–31.CrossRefPubMedPubMedCentral
15.
De Boer SM, Powell ME, Mileshkin LR, Katsaros D, Bessette P, Haie-Meder C, et al. Final results of the international randomized PORTEC-3 trial of adjuvant chemotherapy and radiation therapy (RT) versus RT alone for women with high-risk endometrial cancer. J Clin Oncol. 2017;35S:5502.
16.
McMeekin DS, Filiaci VL, Aghajanian C, Cho J, Kim JW, DiSilvestro PA, et al. Randomized phase III trial of pelvic radiation therapy (PXRT) versus vaginal cuff brachytherapy followed by paclitaxel/carboplatin chemotherapy (VCB/C) in patients with high risk (HR), early stage endometrial cancer (EC): a gynecologic oncology group trial. Gynec Oncol. 2014;134:438.CrossRef
17.
Matei D, Filiaci VL, Randall M, Steinhoff M. A randomized phase III trial of cisplatin and tumor volume directed irradiation followed by carboplatin and paclitaxel vs. carboplatin and paclitaxel for optimally debulked, advanced endometrial carcinoma. J Clin Oncol. 2017;35S:5505.
18.
Decruze SB, Green JA. Hormone therapy in advanced and recurrent endometrial cancer: a systematic review. Int J Gynecol Cancer. 2007;17:964–78.CrossRefPubMed
19.
Fleming GF, Brunetto VL, Cella D, Look KY, Reid GC, Munkarah AR, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol. 2004;22(11):2159–66.CrossRefPubMed
20.
Miller D, Filiaci V, Fleming G, Mannel R, Cohn D, Matsumoto T, et al. Randomized phase III non inferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: a gynecologic oncology group study. Gynecol Oncol. 2012;125:771–3.CrossRef
21.
Aghajanian CA, Filiaci VL, Dizon DS, Carlson J, Powel MA, Alvarez Secord A, et al. A randomized phase II study of paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus and ixabepilone/carboplatin/bevacizumab as initial therapy for measurable stage III or IVA, stage IVB or recurrent endometrial cancer, GOG-86P. J Clin Oncol. 2015;33(Suppl):5500.
22.
Lorusso D, Ferrandina G, Colombo N, Pignata S, Salutari V, Maltese G, et al. Randomized phase II trial of carboplatin-paclitaxel (CP) compared to carboplatin-paclitaxel-bevacizumab (CP-B) in advanced (stage III-IV) or recurrent endometrial cancer: the MITO END-2 trial. J Clin Oncol. 2015;33(Suppl):5502.
23.
Salani R, Backes FJ, Fung MF, Holschneider CH, Parker LP, Bristow RE, et al. Posttreatment surveillance and diagnosis of recurrence in women with gynaecologic malignancies: society of gynecologic oncologists recommendations. Am J Obstet Gynecol. 2011;204:466–78.CrossRefPubMed
24.
Zola P, Macchi C, Cibula D, Colombo N, Kimmig R, Maggino T, et al. Follow-up in gynecological malignancies: a state of art. Int J Gynecol Cancer. 2015;25(7):1151–64.CrossRefPubMed
Metadata
Title
SEOM clinical guidelines for endometrial cancer (2017)
Authors
A. Santaballa
X. Matías-Guiu
A. Redondo
N. Carballo
M. Gil
C. Gómez
M. Gorostidi
M. Gutierrez
A. Gónzalez-Martín
Publication date
01-01-2018
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 1/2018
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-017-1809-9

Other articles of this Issue 1/2018

Clinical and Translational Oncology 1/2018 Go to the issue

Editorial

2017 SEOM guidelines: a multidisciplinary approach

Clinical Guides in Oncology

SEOM clinical guidelines for the treatment of metastatic prostate cancer (2017)

Clinical Guides in Oncology

SEOM clinical guideline for treatment of kidney cancer (2017)

Clinical Guides in Oncology

SEOM clinical guidelines in gestational trophoblastic disease (2017)

Clinical Guides in Oncology

SEOM clinical guidelines for the treatment of head and neck cancer (2017)

Correction

Correction to: SEOM clinical guideline of diagnosis and management of low-grade glioma (2017)
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits